Search academic texts

Information × Registration Number 0212U000509, 0110U000179 , R & D reports Title Complex estimation of the target therapy efficiency in patients with chronic myeloid leukemia taking into consideration immunogenetic, cytogenetic and molecular genetic features of cell's pathological clones popup.stage_title Head Dyagil I.S., Registration Date 16-02-2012 Organization Research Centre for Radiation Medicine popup.description2 To determine the clinical course and dynamics of morphological, cytogenetic, molecular genetic, immunogenetic parameters in patients with chronic myeloid leukemia at different stages of therapy by tyrosinekinase inhibitors were examined 88 patients with CML. Methods - hematologic, cytogenetic, molecular cytogenetic, molecular genetic, immunogenetic, dermatohlifichni, cultural and statistics. Among patients in the chronic phase of CML at 6 months of treatment by imatinib complete hematologic remission was obtained in 96% of cases. In patients who received imatinib therapy 12 months, the optimal response was registered in 44%. There was a tendency to increasing of the frequency of cytogenetic response loss at 12 months in the group of patients with additional chromosomal abnormalities. It was established that the appearance of clone cells with additional Ph-chromosome is unfavorable prognostic sign and may be regarded as a marker to change tactics in curing of patients. The maximum effectiveness of imatinib was shown in appointing him as first-line therapy. Frequency of achieving of complete cytogenetic response after 12 months therapy prevailed in patients in chronic phase patients and patients with low-risk criteria by Sokal. Molecular genetic studies revealed that significantly more to retain achieved in 6 months the optimal response, patients who had transcript b2a2. In patients with CML on imatinib therapy for 6 months increased secretion of IL-2, IFN-gamma and TNF-alfa (p <0.01) were revealed if compared with patients in the disease debut. In patients HLA-genotype significant increasing of carriage of genes HLA-B*51 and HLA-DRB1*11 were determined. It gives reason to consider them as genetic factors of susceptibility to this disease. Genes protectors of chronic myelogenous leukemia: HLA-A*3, HLA-B*08 and HLA-DRB1*04 were established. Results of dermatohlific screening conducted in patients with different response to therapy, defined the relationship between the presence of certain dermatostructures in phenotype and response to treatment within 12 months. Reduced efficiency of progenitor cells colony-formation , the predominance of small clusters in the bone marrow culture and reduction of the colony-formation ability of fibroblast indicate specific inhibition of bone marrow cells proliferation. Among the factors that determine the formation of the optimal and suboptimal response to imatinib therapy in patients with CML it was shown the most significant: term of previous treatment, Sokal index at the time of diagnosis, stage of disease at the time of the imatinib appointment, the presence of additional chromosomal aberrations and type of BCR / ABL transcript. Product Description popup.authors Бєлінська Ірина Володимирівна Балан Валентина Володимирівна Дмитренко Ірина Віталіївна Дмитренко Олена Олександрівна Дягіль Ірина Сергіївна Кучер Олена Володимирівна Мінченко Жана Миколаївна Мішаріна Жана Анатоліївна Федоренко Віра Григорівна Шляхтиченко Тетяна Юрівна Шолойко Валентина Василівна popup.nrat_date 2020-04-02 Close